The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients
Abstract
Systematically titrating bedtime basal insulin added to oral therapy can safely achieve 7% HbA(1c) in a majority of overweight patients with type 2 diabetes with HbA(1c) between 7.5 and 10.0% on oral agents alone. In doing this, glargine causes significantly less nocturnal hypoglycemia than NPH, thu …
Keywords
insulin
Administration
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
humans
pubmed abstract
nih
national institutes of health
national library of medicine
treatment outcome
research support
non-u.s. gov't
algorithms
adult
female
male
aged
middle aged
Clinical Trial
Randomized Controlled Trial
Multicenter Study
Body Weight
drug therapy
combination
diabetes mellitus
oral
blood glucose / drug effects
insulin / administration & dosage*
investigators=[]
affs=[])
hypoglycemic agents / administration & dosage*
pmid:14578243
doi:10.2337/diacare.26.11.3080
matthew c riddle
julio rosenstock
collabauthor(name='insulin glargine 4002 study investigators'
type 2 / drug therapy*
hypoglycemia / chemically induced
hypoglycemic agents / adverse effects
insulin / adverse effects
insulin / analogs & derivatives*
insulin glargine
isophane / administration & dosage*
isophane / adverse effects
long-acting
Access
Citation
ID:
272428
References
Blockchain Verification
Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
272428
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
Creates 1,000,000 NFT tokens for this article
Token Features:
- ERC-1155 Standard NFT
- 1 Million Supply per Article
- Transferable via MetaMask
- Permanent Blockchain Record
Scan with Saymatik Web3.0 Wallet